Echocardiographic assessment of overt or latent unexplained pulmonary hypertension

Canadian Journal of Cardiology

Volumn 19, Issue 5, 2003, Pages 544-548

  Bossone, Eduardo ^a   Chessa, Massimo ^a   Butera, Gianfranco ^a   Carbone, Giannignazio Luigi ^a   Bodini, Bruno Dino ^a   Mazza, Ermanno ^a   Ballotta, Andrea ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Echo Doppler; Pulmonary hypertension

Indexed keywords

NIFEDIPINE; PROSTACYCLIN;

CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; LUNG BLOOD VESSEL; LUNG WEDGE PRESSURE; MEDICAL ASSESSMENT; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; THREE DIMENSIONAL ECHOCARDIOGRAPHY; ECHOGRAPHY; PATHOLOGY;

ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY;

EID: 0038689510     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Rubin LJ. ACCP consensus statement. Primary pulmonary hypertension. Chest 1993;104:236-49.
2. Moraes D, Loscalzo J. Pulmonary hypertension: Newer concepts in diagnosis and management. Clin Cardiol 1997;20:676-82.
3. Rich S. World Symposium on Primary Pulmonary Hypertension. Evian: WHO, 1998.
4. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987;107:216-23.
5. Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr 1999;12:655-62.
6. Park B, Dittrich HC, Polikar R, Olson L, Nicod P. Echocardiographic evidence of pericardial effusion in severe chronic pulmonary hypertension. Am J Cardiol 1989;63:143-5.
7. Goodman DJ, Harrison DC, Popp RL. Echocardiographic features of primary pulmonary hypertension. Am J Cardiol 1974;33:438-43.
8. Hatle L, Angelsen BA, Tromsdal A. Noninvasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. Br Heart J 1981;45:157-65.
9. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62.
10. Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol 1987;9:549-54.
11. Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987;59:662-8.
12. Migueres M, Escamila R, Coca F, Didier A, Krempf M. Pulsed Doppler echocardiography in the diagnosis of pulmonary hypertension in COPD. Chest 1990;98:280-5.
13. Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. J Am Coll Cardiol 1998;31:1367-71.
14. Nakayama Y, Nakanishi N, Sugimachi M, et al. Characteristics of pulmonary artery pressure waveform for differential diagnosis of chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 1997;29:1311-6.
15. Bossone E, Avelar E, Bach DS, Gillespie B, Rubenfire M, Armstrong WF. Diagnostic value of resting tricuspid regurgitation velocity and right ventricular ejection flow parameters for the detection of exercise induced pulmonary arterial hypertension. Int J Card Imaging 2000;16:429-36.
16. Louie EK, Rich S, Brundage BH. Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. J Am Coll Cardiol 1986;8:1298-306.
17. Stojnic BB, Brecker SJ, Xiao HB, Helmy SM, Mbaissouroum M, Gibson DG. Left ventricular filling characteristic in pulmonary hypertension: A new mode of ventricular interaction. Br Heart J 1971;28:16-20.
18. Raffy O, Sleiman C, Mal H, Fournier M, Fournier M, Pariente R. Paradoxical acute brain thromboembolism during prostacyclin (PGI2) acute challenge for primary pulmonary hypertension. Eur Heart J 1996;17:153-4.
19. Young D, Mark H. Fate of the patient with the Eisenmenger syndrome. Am J Cardiol 1971;28:658-69.
20. Himelman RB, Stulbarg M, Kircher B, et al. Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation 1989;79:863-71.
21. Himelman RB, Stulbarg MS, Lee E, Kuecherer HF, Shiller NB. Noninvasive evaluation of pulmonary artery systolic pressures during dynamic exercise by saline-enhanced Doppler echocardiography. Am Heart J 1990;119:685-8.
22. Kuecherer HF, Will M, Da Silva KG, et al. Contrast-enhanced Doppler ultrasound for noninvasive assessment of pulmonary artery pressure during exercise in patients with chronic congestive heart failure. Am J Cardiol 1996;78:229-32.
23. Bach DS. Stress echocardiography for evaluation of hemodynamics: Valvular heart disease, prosthetic valve function, and pulmonary hypertension. Prog Cardiovasc Dis 1997;6:543-54.
24. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: Implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 1999;33:1662-6.
25. Holmegren A, Jonsson B, Sjostarnd T. Circulatory data in normal subjects at rest and during exercise in recumbent position, with special reference to the stroke volume at different work intensities. Acta Physiol Scand 1960;49:343-6.
26. Bevegard S, Holmagren A, Johnson B. Circulatory studies in well trained athletes at rest and during heavy exercise, with special reference to stroke volume and the influence of body position. Acta Physiol Scand 1963;57:26-50.
27. Granath A, Johnsson B, Strandell T. Circulation in healthy old men studied by right heart catheterization at rest and during exercise in supine and sitting position. Acta Med Scand 1964;176:425-46.
28. Granath A, Strandell T. Relationship between output, stroke volume and intracardiac pressures at rest and during exercise in supine position and some anthropometric data in healthy old men. Acta Med Scand 1964;176:447-66.
29. Ekelund LG, Holmgren A. Central hemodynamics during exercise. Circ Res 1967;30:133-43.
30. Wagner PD, Gale GE, Moon RE, et al. Pulmonary gas exchange in humans exercising at sea level and simulated altitude. J Appl Physiol 1986;61:260-70.
31. Palevsky HI. Exercise and the pulmonary circulation. In: Leff A, ed. Cardiopulmonary Exercise Testing. Orlando, Grune & Stratton, 1986;89-106.
32. Groves BM, Reeves JT, Sutton JR, et al. Operation Everest II: Elevated high-altitude pulmonary resistance unresponsive to oxygen. J Appl Physiol 1987;63:521-30.
33. Younes M, Bshouty Z, Ali J. Longitudinal distribution of pulmonary vascular resistance with very high pulmonary blood flow. J Appl Physiol 1987;62:344-58.
34. Ellestad MH. Cardiovascular and pulmonary responses to exercise. In: Ellestad MH, ed. Stress Testing: Principles and Practice, 4th edn. Philadelphia: Davis Company, 1996;11-41.
35. Hopkins SR, Schoene RB, Henderson WR, Spragg RG, Martin TR, West JB. Intense exercise impairs the integrity of the pulmonary blood-gas barrier in elite athletes. Am J Respir Crit Care Med 1997;155:1090-4.
36. West JB. Left ventricular filling pressures during exercise. A cardiological blind spot? Chest 1998;113:1695-7.
37. Grunig E, Janssen B, Mereles D, et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000;102:1145-50.
38. Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985;71:1191-6.
39. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
40. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
41. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
42. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
43. Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998;17:679-85.
44. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5.
45. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
46. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351:24-7.
47. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188-92.
48. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
49. Olschewki H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000;132:435-43.
50. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000;35:176-82.
51. Petkov V, Ziesche R, Mosgoeller W, et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001; 56: 734-6.
52. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
53. Kanemoto N. Electrocardiogram in primary pulmonary hypertension. Eur J Cardiol 1981;12:181-93.
54. Rozkovec A, Montanes P, Oakley CM. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 1986;55:449-58.
55. Eysmann SB, Palevsky HI, Reicheck N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989;80:353-60.
56. Hinderliter AL, Willis PW IV, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.
57. Hinderliter AL, Willis PW IV, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. Am J Cardiol 1999;84:481-4.
58. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
59. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
60. Paciocco G, Martinez FJ, Bossone E, PIelsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647-52
61. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002;121:513-8.
62. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-9.
63. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998;81:1157-61.
64. Ricciardi MJ, Bossone E, Bach DS, Armstrong WF, Rubenfire M. Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: Diminished left ventricular size and leftward ventricular septal bowing. Chest 1999;116:1218-23.
65. Ionescu AA, Ionescui AA, Payne N, Obieta-Fresnedo I, Fraser AG, Shale DJ. Subclinical right ventricular dysfunction in cystic fibrosis. A study using tissue Doppler echocardiography. Am J Respir Crit Care Med 2001;163:1212-8.
66. Sherman HL, Avelar E, Grossmann PM, et al. Transpulmonary passage of Albunex as a marker of intracardiac hemodynamics and outcome in chronic congestive heart failure. Am Heart J 2000;139:782-7.
67. Apfel HD, Shen Z, Gopal AS, et al. Quantitative three dimensional echocardiography in patients with pulmonary hypertension and compressed left ventricles: Comparison with cross sectional echocardiography and magnetic resonance imaging. Heart 1996;76:350-4.
68. Peng L, Carrol J, Murthy TH, et al. Quantitative dynamic global and regional LV shape in normal patients using 3-D echocardiography. J Am Soc Echocardiogr 2000;13:402C. (Abst)